InvaGen receives EIR report for its facility in Hauppauge, New York
Mumbai, Aug. 4 -- Cipla announced that its wholly owned subsidiary, InvaGen Pharmaceuticals (InvaGen) has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection of its manufacturing facility located at Hauppauge, Long Island, New York, USA.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.